News

Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...
Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November.
Exact Sciences stock crashed Wednesday after the company inked a deal for the exclusive eights to Freenome's blood-based ...
MADISON, Wis. -- Exact Sciences is laying off 4% of its overall workforce, including 80 positions in Madison. Approximately ...
EXAS) on Wednesday reported a loss of $1.2 million in its second quarter. The Madison, Wisconsin-based company said it had a ...
Madison-based Exact Sciences is cutting about 4% of its overall workforce, impacting about 200 positions in Wisconsin.
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...
Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...
Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...
Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...
Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.